Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daito Pharmaceutical CoTSE:4577 +3.52%75 Gross Margin % is 20.28% as of Feb. 2026, which is 4% below its 10-year median of 21.03. GuruFocus rates TSE:4577 with a GF Score™ of 75/100 and a GF Value™ of 円1,280.40 (Fairly Valued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Daito Pharmaceutical Co ranks worse than 91.83% on this metric.
TSE:4577's Gross Margin % is ranked worse than 91.83% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs TSE:4577: 18.47
Daito Pharmaceutical Co had a gross margin of 20.28% for the quarter that ended in Feb. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Daito Pharmaceutical Co was -3.80% per year.
Daito Pharmaceutical Co (TSE:4577) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Daito Pharmaceutical Co had a gross margin of 20.28% for the quarter that ended in Feb. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Daito Pharmaceutical Co Gross Margin % Related Terms
Daito Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Daito Pharmaceutical Co (TSE:4577) has a Gross Margin % of 20.28% as of Feb. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Daito Pharmaceutical Co and its competitors. This is near median its historical median of 21.03. Over the past decade, Daito Pharmaceutical Co's Gross Margin % has ranged from 17.05 to 26.36. According to the industry distribution chart, Daito Pharmaceutical Co ranks #866 out of 943 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Daito Pharmaceutical Co's Gross Margin % too high?
Daito Pharmaceutical Co's current Gross Margin % of 20.28% is near median its 10-year median of 21.03. Over the past 10 years, this metric has ranged from a low of 17.05 to a high of 26.36. The Drug Manufacturers industry median Gross Margin % is 48.54. Daito Pharmaceutical Co's value of 20.28% is 58.2% below this industry median. Based on the distribution chart, Daito Pharmaceutical Co ranks #866 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Daito Pharmaceutical Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #866 out of 943 companies for Gross Margin %. This places Daito Pharmaceutical Co in the lower half of its industry. The industry median Gross Margin % is 48.54. Daito Pharmaceutical Co's value of 20.28% is 58.2% below this benchmark. Historically, Daito Pharmaceutical Co's own Gross Margin % has ranged from 17.05 to 26.36 over the past decade. While the company's 10-year median is 21.03 vs. the industry median of 48.54, Daito Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daito Pharmaceutical Co's current Gross Margin % of 20.28% is 58.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current Gross Margin % is 20.28%, which is near median its own 10-year median of 21.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,280.40, compared to a current price of 円1,294.00 — trading 1.1% above its estimated fair value. The current Gross Margin % is 20.28%, which is near median its 10-year median of 21.03 and 58.2% below the Drug Manufacturers industry median of 48.54. Daito Pharmaceutical Co's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Gross Margin % is 20.28% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円1,294.00 is trading 1.1% above its estimated GF Value™ of 円1,280.40.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
Gross Margin %: 20.28% (near median its 10-year median of 21.03)
GF Value™: 円1,280.40 vs. price of 円1,294.00 (1.1% above fair value)
Industry Position: 58.2% below the Drug Manufacturers median (#866 of 943)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
